The Latest Breaking News from Sanofi

Respiratory syncytial virus (RSV) is a very common virus, typically causing infection in children during the colder months. In most cases, RSV causes a mild illness, with symptoms similar to that of a regular cold.

As of Nov. 11, just 29% of Morningstar-covered stocks that reported Q3 earnings beat estimates by at least 10%.

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm

Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.

Paris (AFP) - The European Union has approved a preventative treatment for the very common virus that causes the chest infection bronchiolitis in infants, the companies that developed the drug said Friday.

Though the U.S. economy bounced back after shrinking in the first half of the year, falling consumer spending and the rate hikes to tame high inflation might lead the economy into a recession. Hence, investors looking for passive income could invest in fundamentally sound dividend-paying stocks Pfizer (PFE), Sanofi (SNY),…

Sanofi stock jumped Friday after the company reported better-than-expected third-quarter profit, leading to a guidance boost.

Paris (AFP) - French drug maker Sanofi has revised its outlook for 2022 upwards after reporting strong sales growth in the third quarter on Friday.

Exclusive: halt to production of Shanchol vaccine alarms WHO amid ‘unprecedented’ global outbreaks